Fusobacterium nucleatum and response to treatment in colon and rectal cancer: a systematic review [0.03%]
脆弱拟杆菌与结直肠癌治疗效果的关联：系统性综述
Sara De Dosso,Letizia Deantonio,Giandomenica Iezzi et al.
Sara De Dosso et al.
Fusobacterium nucleatum (Fn) has been implicated in the progression of colorectal cancer (CRC), immune modulation, and resistance to systemic therapies. However, its role as a predictive biomarker of treatment response remains unclear. We c...
Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease [0.03%]
脉络膜黑色素瘤的术前和术后系统性治疗：对一种全身性疾病的系统性控制措施
Dimitra Foteinou,Charalampos Theocharopoulos,Dimitrios Ν Varvoglis et al.
Dimitra Foteinou et al.
Uveal melanoma (UM) is a biologically distinct melanoma subtype in which excellent local tumor control contrasts sharply with a high risk of delayed metastases. The frequent occurrence of distant relapse months to years after index local th...
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective [0.03%]
胃癌抗血管生成治疗：展望2026年及以后的前景：UNICANCER胃肠组(UCGI)观点
Judith Raimbourg,Meher Ben Abdelghani,Valerie Boige et al.
Judith Raimbourg et al.
Antiangiogenic therapies have been extensively investigated in advanced/metastatic gastric cancers, but also in neoadjuvant settings. The anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) monoclonal antibody ramucirumab was the fi...
Julian David Etessami,Giovanni Dalla Via,Emanuela Ferraro et al.
Julian David Etessami et al.
Brain metastases from breast cancer (BCBMs) are a major cause of morbidity and mortality and remain a critical unmet clinical need across molecular subtypes. Their incidence is rising as improved systemic therapies prolong survival in metas...
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck [0.03%]
可切除性头颈部鳞癌新辅助免疫治疗的结局标准及评价指标的规范化研究
Carlo Resteghini,Athanassios Argiris,Pierre Blanchard et al.
Carlo Resteghini et al.
The management of locally-advanced, resectable head and neck squamous cell carcinoma (HNSCC) is undergoing a major shift driven by the integration of neoadjuvant immunotherapy (nIO). The rationale for nIO lies in its administration within a...
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer [0.03%]
胃癌治疗新范式：CLDN18.2精准靶向治疗
Wei Zhou,Wuxuan Mei,Changchun Zeng
Wei Zhou
Claudin 18.2 (CLDN18.2) is an attractive therapeutic target in gastric cancer (GC). Zolbetuximab, a CLDN18.2-targeted monoclonal antibody, has been approved in combination with chemotherapy as a first-line treatment option for patients with...
Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review [0.03%]
超越体表面积：基于CT的机体成分作为预测胰腺导管腺癌化疗毒性和生存期的指标：一项系统综述
Beatriz Chacón-Ovejero,Vilma Pacheco-Barcia,Magda Palka-Kotlowska et al.
Beatriz Chacón-Ovejero et al.
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by a high prevalence of severe muscle wasting (sarcopenia) and fatty muscle infiltration (myosteatosis), yet chemotherapy dosing still relies on body su...
Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes [0.03%]
早期胰腺癌的流行病学、分子特征及临床结局
Fausto Petrelli,Lorenzo Dottorini,Andrea Celotti et al.
Fausto Petrelli et al.
Background Early onset pancreatic cancer (EOPC), defined for the primary analysis as pancreatic ductal adenocarcinoma (PDAC) diagnosed before the age of 50 years, is an increasingly recognised clinical and epidemiological entity. Because pu...
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates [0.03%]
靶向HER2治疗尿路上皮癌：从通路抑制到抗体偶联药物
Hamed Wafa,Nils C H van Creij,Michael Guenther et al.
Hamed Wafa et al.
Urothelial carcinoma (UC) is a biologically and clinically heterogeneous malignancy with persistently poor outcomes in locally advanced or metastatic disease. Although platinum-based chemotherapy and immune checkpoint inhibitors have improv...
Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection [0.03%]
细胞周期治疗：利用细胞周期解耦实现选择性抗癌细胞毒性和保护正常组织
D Izzo,R M Marsicano,D Trapani et al.
D Izzo et al.
The therapeutic index of cytotoxic anticancer agents remains intrinsically constrained by the vulnerability of normal proliferating tissues. Unlike antibiotics, whose selectivity transformed infectious disease prognosis, most chemotherapeut...